Corvus Pharmaceuticals

Yesterday, we shared our Q1 2026 financial results and business update, highlighting continued progress in the clinical development of our ITK inhibitor.    Recent progress includes positive data from cohort 4 of our Phase 1 atopic dermatitis (AD) trial and the initiation of a Phase 2 trial also in AD.     Next week, we will present new immunologic and biomarker data at the Society for Investigative Dermatology (SID), supporting the potential for drug‑free remissions with our ITK inhibitor.    Learn more in our press release: https://lnkd.in/eqx9HTZj

We’re pleased to welcome Andrew Chan to our Board of Directors. He recently served as Senior Vice President, Research Biology at Genentech, leading biological research across therapeutic areas and contributing to several FDA-approved medicines in oncology, neurology, and immunology. His experience will be invaluable as we advance our ITK inhibition platform across immune and inflammatory diseases and cancer.   Dr. Chan brings extensive experience as a physician-scientist in industry and academic medicine. Prior to joining Genentech in 2001, he held longstanding academic and clinical roles at University of California, San Francisco (UCSF) and Washington University School of Medicine.   For more details, read the press release https://lnkd.in/epYZ_kQs

We will host an investor and analyst meeting on May 14, 2026, at 1:30 p.m. ET / 12:30 p.m. CT during the Society for Investigative Dermatology (SID) Annual Meeting. The event will feature commentary from Dr. Albert S. Chiou and Dr. Kavita Sarin.   The meeting will cover data from our Phase 1 clinical trial of our ITK inhibitor in atopic dermatitis data, including new immunologic and biomarker findings that further support the potential for drug-free remissions. This data is also being presented at SID in two oral presentations, including a late-breaker. Learn more in our release: https://lnkd.in/ezgpM6Xd and https://lnkd.in/gVHCEKV

Today, our CEO Richard Miller, MD shared a business update on our Q4 2025 financial results conference call, highlighting our continued progress in the clinical development of our ITK inhibitor.      Recent progress includes announcing positive safety and efficacy data from cohort 4 of our ITK inhibitor Phase 1 atopic dermatitis trial, including in patients previously treated with systemic therapies; initiating our Phase 2 atopic dermatitis trial; and completing a public offering raising net proceeds of $189 million.    In case you missed the webcast, read the press release https://lnkd.in/e7ECz8er  and listen to the replay https://lnkd.in/eEUtD3ad

Join us next week for Corvus’ Business Update and Fourth Quarter 2025 Financial Results. Our CEO, Richard Miller, MD, will lead the call and provide a business update.     To register for the webcast, read our release: https://lnkd.in/eHQcW-Fm  

Join us at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026 at 2:40pm ET for a corporate presentation. For more details and to sign up from the webcast, visit our press release: https://lnkd.in/eeQNRPkk

Our CEO, Richard Miller, MD, joined BiotechTV to discuss follow-up questions on the recently announced data from Cohort 4 of our randomized, placebo-controlled Phase 1 clinical trial evaluating our ITK inhibitor in patients with moderate-to-severe atopic dermatitis.    Thank you to the BioTechTV team—watch the interview below. 

Today, our team shared data from Cohort 4 of our randomized, blinded, placebo-controlled Phase 1 clinical trial evaluating our ITK inhibitor in patients with moderate-to-severe atopic dermatitis.    Cohort 4 data demonstrated positive safety and efficacy results, including additional clinical benefit observed following longer 8-week treatment.    Cohort 1-4 demonstrated positive safety and efficacy results in patients who have received prior systemic therapy including patients who are treatment resistant.    Based on these results, we plan to initiate a Phase 2 trial in Q1 2026.    For more details on the presentation and webcast, read our release: https://lnkd.in/eHT5KiYi

Results from cohort 4 of our randomized, blinded, placebo-controlled phase 1 clinical trial of our ITK inhibitor for atopic dermatitis will be presented during a conference call and webcast on Tuesday, January 20, 2026, at 8:00 a.m. ET / 5:00 a.m. PT. For more details on the presentation, read our release: https://lnkd.in/eZzdmTvH

The peer-reviewed journal Arthritis Research & Therapy recently published a manuscript highlighting the potential of our ITK inhibitor to treat systemic sclerosis. The paper covers preclinical data demonstrating that ITK inhibition can prevent lung damage, inflammation and pulmonary hypertension caused by systemic sclerosis. The research was authored by Professor Yannick Allanore, M.D., Ph.D., Professor of Rheumatology, Université Paris Cité, Institut Cochin, Paris, France. See here for a link to the publication: https://lnkd.in/eienbhpY